KTTA
Pasithea Therapeutics Corp.Company with tickers: KTTA, KTTAW
Market Cap
$17.94M
Shares Outstanding
33,414,448
CIK
1841330
CUSIP
70261F202
13F Activity (30d)
1 filings
1 filers
Website
Visit website
Investor Relations
Investor relations
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $2,942,320 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-4,876,644 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-2,869,482 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.12 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.12 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2021-12-31 | 2022-12-31 |
|---|---|---|
| Clinics1 | $15,062 | $486,559 |